Articles from Bonerge

Bonerge has launched a new randomized, double-blind, placebo-controlled clinical trial investigating how the human body responds to and recovers from circadian disruption following overnight hospital shifts. The study is part of the company’s expanding clinical research program for StanYouth® Urolithin A and focuses on an increasingly important question in sleep and circadian science: how does the body recover after repeated disruption of its normal biological rhythms?

China’s National Medical Products Administration (NMPA) Cosmetic New Ingredient Filing Platform announced a major milestone: MitoYouth® Urolithin A (Filing No.: Guo Zhuang Yuan Bei Zi 20250106), jointly declared by BONERGE and TECH-INNO Health, has been officially approved as a new cosmetic ingredient for use as a skin protectant. This marks a key step in applying circadian rhythm science to cosmetic formulations and reinforces the "Beauty from Within and Without" concept in the anti-aging market.

Bonerge has unveiled its revolutionary anti-aging Product, StanYouth® CR3, a patented formula that bridges Traditional Chinese Medicine (TCM) philosophy with cutting-edge cellular science. Inspired by TCM’s "Senolytic-Repair-Chi" theory, this synergistic complex targets aging at the cellular level, offering a multi-dimensional solution to combat senescence.

In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology.

Bonerge announced the initiation of its clinical trial, focusing on Fisetin, Urolithin A, and Ergothioneine. Involving 108 participants, this trial aims to evaluate their combined effects on skin health and organ rejuvenation when taking orally, providing more reliable options for the market.

In 2024, Bonerge's premium fisetin branded ingredient, BeFisetin®, initiated the SA-GRAS (Self-Affirmed Generally Recognized As Safe) certification process, with completion expected in February 2025. This certification underscores Bonerge's unwavering commitment to product safety, quality control and serves as a key milestone in its expansion into the global fisetin market.

Bonerge is excited to announce the initiation of clinical trials for its high-quality brand ingredients, including GlucoSober and BeFisetin. These trials aim to substantiate the efficacy and safety of the products, providing more reliable options for the market.